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The complexity of the mammalian genome is regulated by heritable epigenetic mechanisms, which
provide the basis for differentiation, development and cellular homeostasis. These mechanisms act on
the level of chromatin, by modifying DNA, histone proteins and nucleosome density/composition. During
the last decade it became clear that cancer is deﬁned by a variety of epigenetic changes, which occur in
early stages of disease and parallel genetic mutations. With the advent of new technologies we are just
starting to unravel the cancer epigenome and latest mechanistic ﬁndings provide the ﬁrst clue as to how
altered epigenetic patterns might occur in different cancers. Here we review latest ﬁndings on chromatin
related mechanisms and hypothesize how their impairment might contribute to the altered epigenome
of cancer cells.
 2012 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Epigenetic mechanisms and their basal functions
In order to gain access to the fundamental information of the
DNA sequence to produce cell type speciﬁc gene expression
signatures, a highly regulated organization of DNA into chromatin
is essential. Long-range silencing of repetitive sequences and
formation of silent heterochromatin but also DNA access for tran-
scription in euchromatin or DNA replication are dependent on
epigenetic mechanisms including DNA methylation, histone
modiﬁcation and remodeling, and non-coding RNA. These mecha-
nisms are interrelated and need to be stably maintained during cell
divisions to conserve cellular identity but also react to cell intrinsic
signals during development or to external factors to adopt to
altered environmental cues.1.1. DNA methylation
Themodiﬁcation of the C5 position of the cytosine base (5mC) is
found in approximately 70e80% of CpG dinucleotides in somatic
mammalian cells and to some extend in non-CpG sequences in
embryonic stem cells (ESC) [1,2]. DNA methylation is the basis for
different epigenetic phenomena such as imprinting, X chromosome
inactivationor the formationof heterochromatin [3]. Generally,DNA
methylation of promoter regions inversely correlates with genex: þ43 1 40400 5179.
. Egger).
nder CC BY-NC-ND license.expression (Fig. 1). Exceptions are CpG islands, which are found in
about 60% of promoters [4]. They have a high CpG density and are
usually kept free of methylation independent of their activity state
[5,6]. However, in cancer cells promoter CpG islands tend to become
hypermethylated, which then causes silencing of the underlying
gene [7]. Intragenic methylation is found at repetitive sequences
suchas satellite repeats and remnants of retroviral insertions such as
LINEs and SINEs in human DNA [1,8]. Gene body methylation is
present in highly expressed genes and it has been speculated that
this may repress transcriptional noise from alternative start sites,
inhibit antisense transcription or direct RNA splicing and relates to
replication timing [9e12]. A direct role for alternative splicing has
recently been attested to methylation-sensitive CTCF binding and
polymerase II pausing at CTCF bound exon boundaries [13].
Comparison of the methylome of different hematopoietic lineages
has identiﬁed a large number of hypomethylated regions (HMRs),
which can be constitutive or lineage-speciﬁc and colocalize with
transcription factor binding sites [14]. Furthermore, complex
patterns of methylation were detected in progenitor cells in HMRs,
which resolved in a lineage-speciﬁc fashion to methylated or
demethylated regions, reminiscentof abivalenthistonemethylation
state found in progenitor cells [14]. Similarly, the deciphering of the
mouse methylome revealed regions of low methylation at distal
regulatory elements, which was linked to binding of tissue speciﬁc
transcription factors [15] (Fig.1). Thus, recent reports have identiﬁed
genomic regions, which are associated with distinct DNA methyla-
tion patterns regulating gene expression proﬁles and chromatin
compartmentalization.
Fig. 1. Complex epigenetic patterns demarcate distinct genomic regions. Genome-wide approaches have provided information on the different epigenetic characteristics of deﬁned
genomic loci. (Top) DNA methylation levels and chromatin states are indicated for an intragenic region, subdivided in expressed and silent status (red color indicates expressed, blue
color silent genes). DNA methylation within promoter regions of genes negatively correlates with expression levels of the gene except in CpG islands, which are usually kept free of
methylation (CpG island, CGI within green rectangle; red line, methylation level of expressed gene; blue line, methylation level of repressed gene; TSS, transcription start site). In
non-CGI promoters (crossed out green rectangle) transcriptional activity inversely correlates with DNA methylation of the promoter. Upstream enhancers (DRE, distant regulatory
element) are demethylated in active genes, whereas they are methylated in repressed genes. Gene body methylation is elevated in expressed genes and shows characteristic spikes
at exon-intron boundaries (indicated by black dashed lines). Furthermore, expressed and silent genes are marked by characteristic chromatin marks, nucleosome density and
histone variants, which together reﬂect the on/off state of a gene (see middle panel of ﬁgure). Note that only selected histone modiﬁcation marks are listed. NDR indicates
nucleosome depleted regions in enhancers, promoters and 30 regions of active genes. BLOCs and LOCKs designate large silent gene-rich regions marked by repressive histone marks
H3K27me3 and H3K9me2, respectively. (Bottom) DNA methylation levels and chromatin composition including histone modiﬁcations, grade of compaction and histone variants are
indicated for intergenic regions and heterochromatin. Inverted arrows on top indicate inverted repeats. These regions show generally high levels of DNA methylation and are
associated with repressive histone marks.
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which is passed on to subsequent cell generations, reprogrammingof DNA methylation occurs during gametogenesis and after fertil-
ization or after artiﬁcial reprogramming of somatic cells into
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tiation speciﬁc demethylation was observed in hematopoietic
progenitors [17] and in murine erythroid progenitors, which
was associated with high DNA replication rates, arguing for
a mechanism of passive demethylation [18]. Modiﬁcation of 5 mC
via oxidation by the TET family of proteins to 5-hydroxymethyl-
cytosine (5hmC) or via deamination to thymine by AID/APOBEC1
followed by base excision repair (BER) was proposed as a possible
mechanism for DNA demethylation [17]. High levels of 5hmC have
been detected in brain tissue and ESCs, which might be a prereq-
uisite for active demethylation by the action of DNA glycosylases or
passive demethylation during replication [19].
1.2. Histone modiﬁcation and remodeling
The coiling of DNA around nucleosome particles is the basis for
the organization of eukaryotic genomes. A multitude of different
posttranslational modiﬁcations of the core histone proteins (H2A,
H2B, H3 and H4) allows for demarcation of speciﬁc chromatin
regions and states, as illustrated by recent genome-wide chromatin
modiﬁcation mapping studies (reviewed in [20]) (Fig. 1). Histone
modiﬁcations can be dynamically added or removed and associate
with both active and repressed regions of chromatin. To date more
than a dozen different histone modiﬁcations have been detected,
which can modify more than 150 conserved residues within
histone proteins [21]. This number of different modiﬁcations has
a high combinatorial potential, which would yield a hugely
complex histone code [22] and it is under debate, whether such
a code exists or whether histone modiﬁcations are a consequence
andmere reﬂection of dynamic processes altering DNA accessibility
such as transcription factor or RNA polymerase II (RNAPII) binding
or chromatin remodeling [23]. Generally, certain histone modiﬁ-
cations such as acetylation or phosphorylation are thought to
change chromatin structure by altering the net positive charge of
the histone proteins, thereby rendering the underlying DNA
sequence information more accessible [24]. Alternatively, histone
modiﬁcations can be recognized by speciﬁc protein domains (e.g.
bromodomains, Tudor domains, chromodomains), which in turn
might enforce or stabilize the chromatin signature and provide
a platform for the recruitment of additional factors [25,26].
Intriguingly, chromatin regulators encompassing histone modiﬁers
and histone modiﬁcation binding proteins are present in a combi-
natorial fashion at distinct genomic loci and frequently bring
together regulators associated with opposing activities [27]. This
might occur counterintuitive, but could provide a dynamic system
for ﬁne-tuning gene expression programs or rapid response to
altered signals and highlights the importance of a balanced level of
chromatin regulators for normal cell function.
Distinct histone modiﬁcations correlate with distinct genomic
regions (Fig. 1); for example H3K4 trimethylation (H3K4me3) with
promoters; H3K4 monomethylation (H3K3me1) with enhancers;
H3K9 acetylation and H3K27 acetylation (H3K9ac, H3K27ac) with
active regulatory regions;H3K36 trimethylation (H3K36me3),H3K79
dimethylation (H3K79me2) and H4K20 monomethylation
(H4K20me1)with transcribed regions and intron/exon usage; H3K27
trimethylation (H3K27me3) with Polycomb repressed regions; or
H3K9 trimethylation H3K9me3 with pericentromeric heterochro-
matin [20,28]. InDrosophila developmental enhancers aremarked by
heterogeneous histone modiﬁcations including H3K4me1, H3K27ac,
H3K79me3 and H3K27me3 and the co-occurrence of H3K27ac,
H3K79me3 and RNAPII was correlated with the spatioetemporal
timing of enhancer activity [29]. The H3K4me1 appeared to repre-
sent a generalmarkpresentonenhancers irrespective of their activity
state and cell type speciﬁcity, whichwas in contrast to earlier reports
[30,31], but is in line with a recent report demonstrating thatPolycomb repressed genes tend to keep permissive enhancers in
differentiated cells, which are marked by the histone variant H2AZ
and H3K4me1 [32]. Presumably, developmental plasticity is estab-
lished through so-called bivalent histone modiﬁcations, which
combine the active H3K4me3 with the inactive H3K27me3 mark in
ESC on silent developmental and differentiation speciﬁc genes.
Duringdifferentiation, these regions canbe resolved into eitheractive
H3K4me3or inactiveH3K27me3marksandenable rapidactivationor
silencing of the underlying genes [33,34].
Aside from gene regulatory functions, which occur in a relatively
local and conﬁned chromatin region, histonemodiﬁcations can also
span large regions, as exempliﬁed by X chromosome inactivation in
female mammals [35]. Large chromatin blocks of H3K27me3
associated with gene silencing have been identiﬁed on mammalian
autosomes [36], and H3K9me2 modiﬁed regions in the megabase
size have been found in differentiated mammalian cells correlating
with silenced genes [37] (Fig. 1).
Further, exchange of canonical histones by variants is connected
to transcriptional activity as well as chromatin structure. Examples
include macroH2A on the inactive X chromosome [38], CENP-A at
centromeres [39] or gH2AX at DNA double strand breaks [40]. The
histone variants H2AZ and H3.3 are enriched at active promoters
and enhancers [41,42] (Fig. 1). Additionally, H3.3 can be incorpo-
rated into telomeres and pericentromeric chromatin [43e45].
Deposition of histone variants can be replication coupled or inde-
pendent and an interesting function has been attested to H3.3
recently. H3.3 deposition via the chaperone HIRAwas linked locally
to RNAPII occupancy at sites of active transcription and a more
global gap-ﬁlling mechanism to protect genome integrity during
transcription or replication was proposed [46].
DNAaccessibility canbe affected by the structure of nucleosomes
and their interaction with DNA by exchanging canonical histones
with histone variants or by histone modiﬁcations, respectively.
Additionally, the position and the density of nucleosomes on the
DNAstring candetermine the level of accessibility. Active geneshave
characteristic nucleosome depleted regions (NDRs) ﬂanked by
positioned nucleosomes upstream of their transcription start sites,
which contain binding sequences for transcription factors [47].
Repressed genes usually lack a NDR, but DNA sequence, binding of
transcription factors and the action of chromatin remodeling
complexes has been suggested to act in a multistep process to
determine local nucleosome composition and density [48] (Fig. 2).
1.3. Non-coding RNA
In recent years, it has become increasingly clear that non-coding
RNAs are important modulators of chromatin regulation and gene
expression. Whole genome and transcriptome sequencing
demonstrated that at least 90% of the genome is actively tran-
scribed, although less than 2% represent protein-coding genes.
Thus, the non-coding part of the transcriptome became a new focus
in gene expression and regulation [49e52].
Currently, two major groups of non-coding RNA players can be
distinguished: small ncRNAs and long ncRNAs (lncRNAs) [52,53].
Small ncRNAsareprocessed fromlongerprecursors andcomprise, in
addition to transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), the
well-studied microRNAs (miRNAs), piwi interacting RNAs (piRNAs),
small nuclear RNAs (snoRNAs) and other less well-characterized
RNAs (for a detailed review on these types of ncRNA and their
function see [54,55]). LongncRNAs (lncRNAs), on the other hand, are
a heterogenous class of mRNA-like transcripts from 200 nt up
to 100 kb which do not code for proteins [53]. They can be tran-
scribed from sense or antisense strand, in a bidirectionalway so that
a coding transcript of the opposite strand is initiated in close prox-
imity, from intronic sequences processed froma transcript and from
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Fig. 2. Setting the epigenetic marks. Establishment of a speciﬁc chromatin environ-
ment can be dependent or independent on DNA sequence. The intrinsic DNA sequence
shows different afﬁnities for nucleosomes. A/T sequences are generally repelling
nucleosomes, whereas G/C sequences are more favorable for nucleosome incorpora-
tion in vitro (left, top). Regular phasing of A/T dinucleotides might help bend the DNA
and facilitate positioning of nucleosomes (left, top). Additionally, sequence-speciﬁc
transcription factors are involved in establishing a deﬁned chromatin state by
recruiting chromatin remodelers (CM) and inﬂuence nucleosome positioning/deple-
tion and histone modiﬁcations of adjacent nucleosomes (left, middle). Alternatively,
non-coding RNA can serve as a scaffold to recruit chromatin remodelers in a sequence
dependent fashion (left, bottom). As a second route, trans acting factors can bind to
methylated DNA or speciﬁc chromatin modiﬁcations and recruit chromatin modifying
complexes, which is essential for maintenance or spreading of epigenetic information
(right, top). Also, non-coding RNA can span large regions of chromatin (e.g. XIST on the
inactive X chromosome) in a sequence independent fashion and enforce a speciﬁc
chromatin environment (right, bottom). Gray cylinders, nucleosomes; black lines,
DNA; red line, speciﬁc DNAmotif; TF, transcription factor; CM, chromatin modiﬁcation/
remodeling complex; black circles, methylated DNA; pink line, non-coding RNA; MBP,
methyl DNA binding protein; HMBP, histone modiﬁcation binding protein; small
colored circles and hexagons indicate different histone modiﬁcations as indicated in
Fig. 1.
Table 1
Selected lncRNAs and interaction partners.
lncRNA Interaction/Target Function References
Polycomb repressive complexes (PCR)
XIST PCR2 Silencing of X chromosome [84]
HOTAIR PCR2 Targets PCR2 complex to HOXD
locus
[118]
ANRIL PCR2 and PCR1 Targets PCR complexes to
INK4b-ARF-INKa locus
[119e121]
Histone methyltransferases (HMTs)
AIR HMT G9a Silencing of maternally expressed
Igf2r/Slc22a2/Slc22a3
[87]
Kcnq1ot1 PCR2 and HMT G9a Lineage-speciﬁc silencing of the
Kcnq1 locus
[88]
HOTTIP WDR5/MLL Activation of the HOXA cluster [170]
Histone demethylases
HOTAIR LSD1/CoREST/REST HOXD locus regulation, silencing
of neuronal speciﬁc genes
[171]
Transcription factors/mRNA processing
lincRNA-
p21
Repressive hnRNP-K
complex
Targets hnRNP-K to repress p53
target genes
[90]
NRON NFAT Affects transcription factor acitvity [172]
PANDA NF-YA Delimits apoptosis by inhibiting
NF-YA
[91]
miRNAs
PTENP1 miR-17, miR-19 Decoy for miRNAs targeting tumor
suppressor PTEN
[124]
HULC miR-372 Upregulated in liver cancer [125]
linc MD1 miR-133 Regulation of muscle
differentiation
[173]
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that they make up the bulk of the human transcriptome, excluding
ribosomal and mitochondrial RNA [57,58]. Functional lncRNAs
fulﬁll important regulatory roles in gene expression and regulation
by assembling protein complexes and localizing them to their
genomic target DNA sequence [59]. Long intergenic non-coding
RNAs (lincRNAs) have been identiﬁed at intergenic sites outside
protein-coding genes containing H3K4me3 and H3K36me3
domains [60]. Many of these biological active lincRNAs can phys-
ically associate with chromatin remodeling complexes such as
PCR2 [61] and are needed for pluripotency and differentiation [62]
(Table 1).
Another class of non-coding RNAs constitute the recently
discovered transcribed ultraconserved regions (T-UCRs) [63,64],
which are transcribed from evolutionary ultraconserved regions
found in the human, rat and mouse genome [65]. They show
aberrant expression in several cancers, including adult chronic
lymphocytic leukemia, colorectal and hepatocellular carcinomas
and neuroblastomas [64e66]. Although distinct T-UCR expression
signatures are associated with speciﬁc cancer types and their high
sequence conservation across species argues for functional prop-
erties, their precise mode of action in the cell is still unknown [64].Noteworthy, a recently introduced method called ChIRP (Chro-
matin Isolation by RNA Puriﬁcation) has the potency to shed light
on the complexity of RNA-chromatin or RNA-DNA-protein inter-
actions on a genome-wide scale. This technology was used to map
genome-wide interaction sites of three different lncRNAs including
HOTAIR, and has revealed focal, sequence-speciﬁc binding at
numerous sites in the genome [67].
1.4. Interrelations of different epigenetic mechanisms and targeting
of epigenetic modiﬁcations
The different epigenetic layers described above are interrelated
and can both reinforce each other and inhibit opposing functions. In
order to establish a repressive chromatin environment DNA meth-
ylation and repressive histone modiﬁcations are combined within
the same chromatin regions. Methylation of H3K9 is found in
regions of DNA methylation, whereas H3K4me3 and DNA methyl-
ation occur mutually exclusive. Different HMTs including G9a,
SUV39H1, EZH2 can direct DNA methylation via direct or indirect
recruitment of DNMTs [68e70], whichmight be amechanism for de
novomethylation of DNA in ESC but appears to be nonessential for
maintenance of methylation in differentiated cells [71].
The ubiquitin multi-motif protein UHRF1 is a central player in
targeting repressive chromatin marks. It contains a SRA domain,
which binds to hemimethylated DNA, a Tudor domain binding to
methylated H3 (H3K9me3) and a PHD ﬁnger interacting with an
unmodiﬁed arginine residue within H3 (H3R2) [72e74]. Further-
more, UHRF1 interacts with DNMTs, G9a and HDAC1 and thereby
unites various enzymes that can provide a repressive chromatin
environment [75e77]. Interestingly, UHRF1 also recruits the H2AK5
actetyltransferase TiP60 thus integrating a multitude of different
epigenetic signals [78]. A further example for the link between
DNA methylation and histone modiﬁcations represent methyl C
binding proteins such as MeCP2, which interact with co-repressor
complexes including HDACs and HMTs [79,80]. Interestingly,
a recent report shows that components of the piRNA pathway are
required to target de novo DNA methylation to an imprinted region
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imprinted regions can be regulated by non-coding piRNAs [81].
Although we can dissect different functional genomic areas by
their chromatin modiﬁcation pattern, we still don’t understand the
mechanism underlying this patterning and whether epigenetic
marks such as posttranslational histone modiﬁcations are cause or
consequence of chromatin states [23] (Fig. 2). Evidence is accu-
mulating, that the DNA sequence per se is at least in part able to
direct chromatin structure and modiﬁcation. This involves posi-
tioning of nucleosomes in a sequence dependent manner [82].
Additional binding of transcription factors and recruitment of
chromatin remodeling complexes are essential to demarcate active
regions and to adjust nucleosome composition, occupancy and
positioning [48]. Interestingly, de novo methylation of DNA is also
mediated by genetic elements, which are found in promoters and
contain binding motifs for transcription factors [83].
Another targeting mechanism of epigenetic modiﬁcations relies
on lncRNAs, which function as “adaptor platforms” for interactions
between chromatin and chromatin remodeling complexes and are
able to recruit anddirect chromatin remodeling complexes to speciﬁc
loci in the genome [59] (Fig. 2). The longest-known examples for this
are lncRNAs involved in epigenetic silencing and imprinting, such as
the X-inactivation promoting lncRNA XIST, which recruits the Poly-
comb repressive complex (PRC) to silence the X chromosome from
which it is transcribed [84] and TSIX, which is transcribed from the
opposite strand and regulates XIST levels during X-inactivation [85].
Other lncRNAs involved in imprinting processes are the paternally
expressed lncRNAAIR, which is required for silencing thematernally
expressed protein-coding genes Igf2r/Slc22a2/Slc22a3 [86] and
inhibits expression by targeting the H3K9 histonemethyltransferase
G9a to the Slc22a3 promoter [87], and paternally expressed lncRNA
Kcnq1ot1, which mediates lineage-speciﬁc silencing of the Kcnq1
locusby interactionwith thePRC2complexandG9aHMTinplacenta,
but not in fetal liver [88].
Furthermore, loss of function studies and analyses of custom-
designed microarrays demonstrate involvement of functional
lncRNAs in development and differentiation [62,89]. Speciﬁc sets of
lncRNAs are needed to keep embryonic stem cells in a pluripotent
state and promote differentiation by association with not only
chromatin modiﬁers but also speciﬁc transcription factors such as
SOX2 and REST [89].
lncRNAs can also contribute tomodulation of cell cycle networks
in the cell, such as the recently discovered lincRNA-p21, which is
induced byp53 andmediates gene repression of p53 target genes by
associating with repressor complex heterogeneous nuclear ribo-
nucleoprotein K (hnRNP-K) and targeting the complex to previously
active genes [90]. Other examples for lncRNAs in the p53 network
are the p53-induced lncRNA PANDA and the maternally expressed
gene 3 (MEG3). PANDA is transcribed from the CDKN1A locus and
delimits apoptosis afterDNAdamage [91] byspeciﬁcallybindingand
inhibiting NF-YA, a nuclear transcription factor that is responsible
for activating genes related to apoptosis. MEG3 can activate both
p53-dependent and p53-independent pathways and has tumor
suppressive functions [92]. Interestingly, it was shown that partial
replacement of MEG3 RNA with unrelated sequences did not alter
p53 activation, indicating that lncRNA function largely depends on
secondary structures and that lack of sequence conservation, which
is observed for many lncRNAs, does not affect functionality.
2. Alterations in cancer
2.1. Altered epigenetic patterns
The epigenome of cancer cells displays numerous alterations in
comparison to the epigenome of their normal counterpart. Changesin DNAmethylation include a genome-wide loss and a regional gain
of DNA methylation. This causes on one hand genomic instability
and deregulation of tissue speciﬁc and imprinted genes and on the
other hand silencing of tumor suppressor genes e controlling cell
cycle, apoptosis or DNA repair e by hypermethylation of their
promoter CpG islands [3,7]. Interestingly, no global hypo-
methylation but rather a directed hypomethylation at satellite
repeats could be detected in malignant peripheral nerve sheath
tumors using a genome-wide approach [93].
Unusually high frequency of DNA methylation at CpG rich sites
was termed CIMP (for CpG island methylator phenotype) and was
ﬁrst identiﬁed in colorectal cancer [94]. CIMP is associated with
diverse clinicopathological characteristics such as patient age,
gender, tumor location, microsatellite instability and genetic
mutation in theBRAFgene [95]. Interestingly, CIMPcanalsobe found
in other tumor entities such as glioma or breast cancer, where it also
allows for a sub-classiﬁcation of tumors and determines metastatic
potential, respectively [96,97]. In analogy to genetic mutation,
tumors seemtoaccumulate higher levels ofDNAmethylationduring
tumor progression and genome-wide proﬁling of DNA methylation
has proven useful for tumor classiﬁcation of different tumor types
[98e100]. These deﬁned alterations are currently evaluated for their
use as biomarkers for diagnosis, prognosis and prediction of therapy
response for different cancers [101].
Another target of aberrant DNA methylation in cancer are CpG
island shores, deﬁned as approximately 2 kb regions surrounding
CpG islands. These regions were initially identiﬁed hyper-
methylated in colorectal cancer and represent regions of tissue
speciﬁc methylation in normal tissues [102]. Methylation of shore
regions is related to gene expression and has also been detected in
different tumor cell lines and nerve sheath tumors [93,103]. In
contrast, no differential methylation of shore regions was detected
in different lineages of the murine immune system [104].
Tumor heterogeneity presents an obstacle for therapeutic
intervention and cure. Stochastic methylation variability was
detected in cancer speciﬁc differentially methylated regions
(cDMRs), which might contribute to tumor heterogeneity [105].
Further, large hypervariable blocks covering half the genome show
differences in gene expression patterns, involving genes that
regulate tumor-associated processes such as cell division and
matrix remodeling [105]. This heterogeneity of methylation
patterns might be the foundation for the selective advantage of
tumor cells and provide a cellular mechanism of evolution [106].
Additional insight into the cancer methylome has been gained
from a recent study in primary colon cancer [107]. Single CpG
resolution genome-wide bisulﬁte sequencing enabled the identi-
ﬁcation of large hypomethylated regions, covering more than half
of the genome. These regions coincided with late replication foci
and nuclear lamina associated domains. This study thus proposes
the 3D chromatin architecture to be involved in epigenetic
reprogramming in cancer cells. Another link between chromatin
architecture and DNA hypermethylation of tumor suppressor genes
stems from the ﬁnding that loss of CTCF binding in multiple tumor
cell lines coincides with silencing of p16INK4a and the loss of an
upstream chromatin boundary [108].
Numerous changes in modiﬁcation patterns have also been
observed at the level of posttranslational histone modiﬁcations
[109]. The loss of repressive heterochromatin is reﬂected by
a depletion of repressive histone marks such as H4K20me3 and
H4K16ac in these regions [110]. Further, H3K27me3 seems to occur
mutually exclusive to DNA methylation and promote de novo
silencing of genes in different cancers [6,111]. Many developmental
genes that are silenced by H3K27me3 in embryonic stem cells are
silenced by DNA methylation in cancer cells, establishing an
epigenetic switch from a dynamic to a more stable silencing system
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Generally, changes in histone modiﬁcation patterns were reported
in a variety of tumors and correlated to tumor stage and prognosis,
however with contradicting results [109]. Since histone modiﬁca-
tion patterns are very dynamic and can be easily erased by
opposing enzymes, it seems that a regulated balance of these
modiﬁers needs to be present within a cell. Shifting the balance to
either side might therefore result in different outcomes and either
promote or restrict tumor proliferation. This is highlighted by the
recent ﬁnding that the histone deacetylase HDAC1, which was
previously associated with cell cycle arrest, can induce tumor
proliferation in a teratoma mouse model [115,116].
Altered epigenetic patterns in cancer cells are also associated
with the deregulation of lncRNAs and subsequent re-positioning of
chromatin modifying complexes. For example, increased expres-
sion of the lincRNA HOTAIR was found in primary and metastatic
breast tumors [117]. Overexpression of HOTAIR, which is normally
expressed antisense to the HOXC locus during development and
targets the PCR2 complex to the HOXD locus [118], leads to different
PCR2 occupancy at chromatin sites, altered H3K27 methylation
patterns resembling those of embryonic ﬁbroblasts and increased
cancer invasiveness in breast cancer cells [117]. Another lncRNA
involved in targeting of PCR complexes to tumor suppressor genes
is antisense non-coding RNA in the INK4 locus (ANRIL) [119,120].
ANRIL is transcribed from the antisense strand at the INK4b-ARF-
INK4a locus, which is an important regulator of cell cycle
progression, apoptosis and cellular senescence [121,122]. By
recruiting PCR1 and PCR2 complexes to form heterochromatin
surrounding the INK4b-ARF-INK4a locus, ANRIL mediates silencing
of these tumor suppressor genes.
According to an interesting new hypothesis non-coding RNAs
can, besides assembling chromatin complexes and modulating cell
cycle networks, act as decoys for miRNAs when they contain
speciﬁc microRNA binding sites. This in turn has implications on
the expression of other mRNAs and regulatory networks normally
targeted by the respective miRNA [123]. An example for this
competing endogenous RNA (ceRNA) is the transcribed PTENP1
pseudogene, which contains many microRNA response elements
(MREs) also present in the tumor suppressor PTEN. PTENP1 has
been shown to be able to regulate cellular levels of PTEN by
detracting miRNAs from PTEN mRNA and is selectively lost in
cancer, indicating a tumor suppressor function [124]. Another
example for an oncogenic “endogenous sponge” is the highly
upregulated in liver cancer (HULC) lncRNA, which sequesters miR-
372 and in turn induces its own transcriptional up-regulation in
liver cancer [125].
2.2. Mutations in epigenetic enzymes
Chromatin modifying enzymes such as HMTs, histone acetyl-
transferases (HATs) and HDACs have been implicated in the
pathology of leukemia, either as direct or indirect partners of
oncofusion proteins [126]. The HATs MOF, MOZ or p300/CBP and
the HMT MLL are frequently found in translocations in acute
myeloid leukemia (AML) [127], whereas indirect recruitment of co-
repressor complexes including HDACs has been found in PML/
RARalpha and PLZF/RARalpha fusions in acute promyelocytic
leukemia (APL) [128,129].
Advances in next generation sequencing technologies have
resulted in the discovery of novel somatic mutations driving
different cancers [130]. Intriguingly, numerous chromatin related
enzymes and proteins were among the newly identiﬁed genes
[109,131]. For example, the HMT EZH2, which has previously been
attested oncogenic potential in different solid cancers such as
prostate or breast cancer, is frequently mutated in hematologicalmalignancies together with other members of the PRC2 such as EED
and SUZ12 [132]. Interestingly, inactivating mutations were iden-
tiﬁed in myeloid disorders [133,134] and in T-ALL (acute lympho-
blastic leukemia) [135], whereas activating mutations leading to
hyper-trimethylation of H3K27me3 were associated with two
mutations (Y641, A6779) in follicular lymphoma and other B-cell
lymphomas [136e138].
Mutations associated with DNA methylation have also been
described in hematological disorders. The de novo methyltransfer-
ase DNMT3a was found mutated in acute myeloid leukemia (AML)
and myelodysplastic syndrome [139e141]. The family of TET
proteins has been implicated in DNA demethylation in ES cells and
is frequently found mutated in myeloid disorders [142]. This is
related to lower levels of 5-hydroxymethyl-Cytosine (5hmC) but
surprisingly also to DNA hypomethylation in affected patients
[143]. TET function can also be affected by mutations in IDH1 and
IDH2 genes, which cause accumulation of 2-hydroxyglutarate
inhibiting TET2 [144]. Somatic mutations of IDH1 have been asso-
ciated with a CIMP phenotype in glioma [96]. An oncogenic coop-
eration was suggested recently for DNMT3a and TET2 in T-cell
lymphoma indicated by a frequent co-occurrence of mutations in
both genes, where 73% of patients with DNMT3a mutations also
harbored TET2 mutations [145].
Two recent publications independently demonstrated that
mutations at two critical sites of posttranslational modiﬁcations in
the histone H3 variant H3.3 are frequently detected in different
forms of brain tumors [146,147]. Schwatzentruber et al. further
found somatic mutations in the H3.3-ATRX-DAXX chromatin
remodeling pathway, which is needed for the incorporation of
histone H3.3 into pericentromeric heterochromatin, in 44% of
pediatric glioblastoma multiforme (GBM). This was accompanied
by alternative telomere lengthening highlighting the important
role of H3.3 for genome integrity and chromatin architecture [46].
An unexpected role in chromatin regulation was recently
ascribed to the tumor suppressor BRCA1 [148]. Using nestin-Cre
speciﬁc deletion of Brca1 in murine neural stem cells, Zhu et al.
discovered an impaired heterochromatin structure in knockout
cells, which was associated with increased transcription of satellite,
repeats. This was due to the loss of histone H2A ubiquitylation
at pericentromeric heterochromatin, which was dependent on the
ubiquitin ligase function of BRCA1. Increased transcription of satel-
lite repeats was associated with DNA damage and genomic insta-
bility and was also detected in BRCA1 deﬁcient murine and human
breast cancers. Thus, the authors propose that the tumor suppres-
sive function of BRCA1might be largely dependent on its regulation
of pericentromeric heterochromatin, which allows for controlled
cell division and genome integrity [148]. Overexpression of satellite
repeatswas also identiﬁed inpancreatic and other epithelial cancers
lately, indicating that disruption of heterochromatin may result in
genomic instability in a variety of human cancers [149].
2.3. Possible causes of aberrant epigenetic patterns
In order to recognize the source of aberrant epigenetic patterns,
we need to understand how epigenetic pathways work in their
normal environment. Recent literature has provided us several
options (Fig. 3). First, alterations of epigenetic patterns such as
aberrant DNA methylation could arise stochastically due to loss of
ﬁdelity or mutation of epigenetic enzymes [109]. This is supported
by the ﬁnding that aging results in a loss of the global DNA meth-
ylation content [150] and by a large heterogeneity in genome-wide
methylation patterns of different cancers [105].
The nucleus has to accommodate DNA in an ordered fashion,
to allow for regulated gene expression. Using Hi-C to resolve
the 3-dimensional genome architecture, LiebermaneAiden et al.
Fig. 3. Altered nuclear and epigenomic structure of cancer cells. In normal cells, the nucleus is subdivided into active (yellow) and inactive (gray) territories. Inactive territories are
located close to the nuclear lamina (blue circle) and contain inactive, hypermethylated regions (black circles) that are tightly packed into nucleosomes with repressive histone marks
(red cylinders). Active regions are found in the nuclear center, and contain “transcription factories” (green shapes), which are composed of speciﬁc transcription factors, RNAPII,
chromatin remodelers and CTCF/cohesin proteins for looping chromatin into these areas. Promoters of active genes (red lines) are unmethylated (white circles) and marked by
positive histone marks (green cylinders). Permanent stress (such as chronic inﬂammation (CI), UV exposure, reactive oxygen species (ROS)) might induce a stable epigenetic switch
via mutation in epigenetic enzymes (I), mistargeting or altered composition of epigenetic complexes (II) or altered nuclear architecture linked to stress speciﬁc gene expression
patterns (III). The altered nuclear morphology of cancer cells is associated with re-arranged active and inactive territories and chromatin, global DNA demethylation (white circles)
and local DNA hypermethylation at CpG islands, which results in silencing of underlying genes (indicated by blue lines, black circles within blue lines indicate methylated promoter
CpG islands). Transcription factories contain a tumor cell speciﬁc set of proteins (red shapes) such as transcription factors and maintain a tumor cell speciﬁc gene expression proﬁle.
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gated open and closed chromatin states [151]. This suggests
a territorial arrangement of nuclear architecture, which is sup-
ported by the ﬁnding that heterochromatic regions and repressed
genes tend to be associatedwith the nuclear lamina, whereas active
chromatin is moved away from the lamina [152,153]. Clustering of
Polycomb regulated HOX genes and the organization of repressive
chromatin into Polycomb bodies lends further support to these
ﬁndings [154]. Actively transcribed regions of the genome have
been thought to cluster in so-called “transcription factories” [155].
Recent data substantiate this model, which suggests that genes
regulated by speciﬁc transcription factors are clustered and looped
around factories of concentrated RNAPII [156]. The ﬁrst 3D inter-
action map of RNAPII occupied sites was recently established using
chromatin interaction analysis by paired-end-tag sequencing
(ChIA-PET) [157]. RNAPII dependent interaction sites consist of
extensive promoterepromoter interactions between proximal and
distant genes yielding multi-gene complexes that cooperatively
regulate their activity and are enriched for active chromatin marks.
One might envision a model, in which speciﬁc transcription factors
assemble genes via promoter/enhancer binding assisted by
proteins involved in chromatin looping and organization such as
CTCF, cohesin or chromatin remodelers [156e160]. Nuclear struc-
ture including chromatin texture is altered in tumor cells and used
by pathologists for diagnosis of malignancy. Molecularly this would
hold a considerable potential for large-scale rearrangements of
genomic organization causing deregulated gene expression
patterns and aberrant chromatin structure, which is in line with
recent ﬁndings related to aberrant DNA methylation in cancer cells
and provides a second route to altered epigenetic patterning in
cancer [37,105,107,161].
Finally, alterations in the cancer epigenome might result from
mistargeting or altered composition of epigenetic complexes. By
inducing cellular oxidative stress O’Hagan et al. showed, that
a complex consisting of DNMTs andHDACs is formed and recruited to
the sites of damaged DNA. Components of the complex are recruited
fromnon-GC-rich toGC-richareas. The authors detect similar changesin an in vivo inﬂammatory model and suggest, that delocalization of
key epigenetic enzymes upon cellular stress might be the cause of
global and local epigenetic alterations of cancer cells [162].
2.4. Signaling to the cancer epigenome
Epigenetic patterns are initially established as a consequence of
developmental cues and are maintained even after the initiating
signal is removed. For example, early differentiation programs are
turned on in response to speciﬁc transcription factors and are
upheld in the determined lineage. Nonetheless the epigenome
retains some level of plasticity and can be shaped by environmental
factors. Polycomb group (PcG) proteins are essential to maintain
the cellular memory by acting in these aforementioned ways of
both stabilizing cell fate decisions but also regulating gene
expression patterns in response to extrinsic signals [163]. This has
been exempliﬁed by the induction of transdetermination in
Drosophila via suppression of PcG proteins by JNK kinase signaling
[164], which links upstream kinase signaling with chromatin
modiﬁcations. A further connection between kinase signaling in
response to external factors and PcG proteins has been made by
the ﬁnding that the PRC2 component EZH2 can be directly
phosphorylated at different sites by a number of cell cycle depen-
dent and stress induced kinases [165]. Although the effects of site
speciﬁc phosphorylation of EZH2 are somewhat controversial, it
can be anticipated that they regulate EZH2 interaction with other
PRC members, enzymatic activity or targeting to chromatin sites.
Aside from modiﬁcation of chromatin related proteins, stress
induced kinases can directly modify histone tail residues as
recently demonstrated for JNK during stem cell differentiation into
neurons [166]. Recent work has identiﬁed numerous upstream
kinases that directly act on chromatin in response to cytokines,
growth factors or ultraviolet light and are involved in transcrip-
tional regulation, chromatin condensation, apoptosis and DNA
damage repair [167]. Combinatorial histone modiﬁcation patterns
have been observed among the many possible modiﬁcations of
histone tails. Related to histone phosphorylation, a crosstalk
M.R. Hassler, G. Egger / Biochimie 94 (2012) 2219e22302226between phosphorylation and acetylation of neighboring residues
has been detected. For example, H3S10 phosphorylation is facili-
tating the acetylation of the nearby H3K9/K14 marks and has an
important function for the induction of different genes in response
to stress (for details see also review by Sawicka and Seiser this
issue). Additionally, phosphorylation of the H3 tail can alleviate the
repressive function of histone methylation on H3K9 and H3K27 by
releasing HP1 or PRC2 from chromatin, respectively [167]. Thus,
kinase signaling targets transcription factors, chromatin modiﬁers
and chromatin itself to robustly induce transcriptional responses to
external stimuli and if deregulated might lead to local and global
changes in chromatin structure and gene expression patterns as
observed in various cancers.3. Conclusions
Research of the last decade has highlighted the essential role of
epigenetic alterations in cancer development and progression
[168]. Latest technologies have allowed for the analysis of the
cancer epigenome and have resulted in important discoveries,
which provide the basis for new concepts of how epigenetic
alterations might emerge. We are now able to look at the cancer
epigenome from a bird’s eyes view and we are just beginning to
understand how alterations in nuclear architecture and global
chromatin, as observed by pathologists since more than 150 years,
are related to epigenetic mechanisms [169]. Based on latest litera-
ture we can envision different pathways that might cause epige-
netic alterations in cancer cells as observed by genome-wide
epigenomic proﬁling (Fig. 3). (I) Mutations in chromatin related
enzymes such as DNMTs, histone modiﬁers or chromatin remod-
elers might induce stochastic changes in the epigenome causing
global changes in chromatin. (II) Faulty targeting (e.g. by lncRNAs or
transcription factors) or altered composition of epigenetic
complexes can lead to global and gene speciﬁc changes in the
epigenetic signature. (III) Changes in the spatioetemporal organi-
zation of nuclear architecture or loss of boundaries might cause
altered nuclear territories, disrupt ordered epigenetic patterns and
induce altered gene expression programs. All three pathways could
result from altered external signaling due to permanent stress and
act in concert to lock in the cancer epigenome.Acknowledgments
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